CA125 and Ovarian Cancer: A Comprehensive Review
University of Toronto · Women's College Hospital · +3 more institutions
Abstract
Ovarian cancer is the second most lethal gynecological malignancy. The tumour biomarker CA125 has been used as the primary ovarian cancer marker for the past four decades. The focus on diagnosing ovarian cancer in stages I and II using CA125 as a diagnostic biomarker has not improved patients' survival. Therefore, screening average-risk asymptomatic women with CA125 is not recommended by any professional society. The dualistic model of ovarian cancer carcinogenesis suggests that type II tumours are responsible for the majority of ovarian cancer mortality. However, type II tumours are rarely diagnosed in stages I and II. The recent shift of focus to the diagnosis of low volume type II ovarian cancer in its…
Citation impact
- FWCI
- 37.62
- Percentile
- 100%
- References
- 194
Authors
6- PCParsa Charkhchi
University of Toronto, Women's College Hospital
- CCCezary Cybulski
International Hereditary Cancer Center, Pomeranian Medical University
- JGJacek Gronwald
International Hereditary Cancer Center, Pomeranian Medical University
- FWFabian Wong
University of Toronto, Women's College Hospital
- SASteven A. Narod
University of Toronto, Women's College Hospital, Public Health Ontario
Topics & keywords
- Ovarian cancer
- Medicine
- Oncology
- Stage (stratigraphy)
- Cancer
- Biomarker
- Malignancy
- Internal medicine
- Good health and well-being